NCT01897714View on ClinicalTrials.gov

Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

March 31, 2020

Conditions
Relapsed and/or Relapsed-refractory Multiple Myeloma
Interventions
DRUG

Melflufen

DRUG

Dexamethasone

Trial Locations (7)

27514

Universtity of North Carolina, Chapel Hill

48201

Karmanos Cancer Center, Detroit

02215

Dana Farber Cancer Institute, Boston

Unknown

Vejle Hospital, Vejle

Turin Hospital Myeloma Unit, Turin

Erasmus University Medical Center, Rotterdam

Sahlgrenska Hospital, Gothenburg

Sponsors

Lead Sponsor

Oncopeptides AB
All Listed Sponsors
lead

Oncopeptides AB

INDUSTRY

NCT01897714 - Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients | Biotech Hunter | Biotech Hunter